In conclusion, we demonstrate, using transgenic models and shRNA knockdown, that PTH1R signaling is critical in both breast cancer cells and osteoblasts for the inhibitory actions of PTH treatment on bone metastases. This evidence concerns the gene PTH and breast carcinoma.